HOLLISTON, Mass.--(BUSINESS WIRE)--Aug. 29, 2006--Harvard Bioscience, Inc. (Nasdaq: HBIO), a global developer, manufacturer, and marketer of a broad range of specialized products used to advance life science research, today announced that its President, David Green, will present at the Thomas Weisel Partners Healthcare Conference at 8:35 am local time on Thursday September 7, 2006 at the Four Seasons hotel in Boston. The presentation audio will be simultaneously webcast and will be accessible from the HBIO website www.harvardbioscience.com under the "Presentations & Webcasts" tab and at http://www.veracast.com/webcasts/twp/healthcare06/86202442.cfm until October 8, 2006. An archive of this presentation will also be available on our website. Mr. Green's presentation will be available at the conference or can be downloaded from our website by clicking on the investor presentation icon. The presentation will cover the historical and expected future performance of the business. There will be a question and answer session following the presentation. Some of the information to be presented by Mr. Green or provided in response to questions may contain information that has not previously been disclosed. Additionally, any material financial or other statistical information presented in our presentation or in the question and answer session, which has not been previously disclosed will be archived and available in the Investor Relations section of our website.
About Harvard Bioscience
Harvard Bioscience is a global developer, manufacturer, and marketer of a broad range of specialized products, primarily scientific instruments and apparatus, used to advance life science research at pharmaceutical and biotechnology companies, universities and government laboratories worldwide. HBIO sells its products to thousands of researchers in over 100 countries through its 1,100 page catalog (and various other specialty catalogs), its website and through its distributors, including GE Healthcare, Fisher Scientific and VWR. HBIO has sales and manufacturing operations in the United States, the United Kingdom, Germany, and Austria with additional facilities in France and Canada. For more information, please visit www.harvardbioscience.com.
For investor inquiries, please call (508) 893-8066. Press releases may be found on our web site, http://www.harvardbioscience.com.
CONTACT: Harvard Bioscience, Inc. 508-893-8999 David Green President email@example.com or Chane Graziano CEO firstname.lastname@example.org or Bryce Chicoyne CFO email@example.com SOURCE: Harvard Bioscience, Inc.
The information contained within this and other Harvard Bioscience Web pages should be deemed accurate and current as of the date of the most recent update, or if no update information has been provided, the date of issuance. Harvard Bioscience assumes no responsibility for any misincurrances or misstatements which occur as the result of the reading of dated material. Users are strongly encouraged to check dates of issuance and most recent update of any information contained within, or linked to, Harvard Bioscience’s web site. For Harvard Bioscience’s most current information please reference Harvard Bioscience public filings with the Securities and Exchange Commission located at http://www.sec.gov.